Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

NCT04230265 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped business decision by sponsor

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Cyclophosphamide (Non-IMP)
DRUG: Fludarabine (Non-IMP)
DRUG: TM123 (IMP)
DRUG: UniCAR02-T (IMP)

Sponsor

AvenCell Europe GmbH

Collaborators

[object Object]